BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

Highlights,Revisions in market valuation reflect varying assessments of BioNTech's standing.,Institutional stakeholders adjust their holdings in response to industry trends.,Continued progress in the ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are covering the company, MarketBeat.com reports. Three research ...

The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

H.C. Wainwright lowered the firm’s price target on BioNTech (BNTX) to $145 from $150 and keeps a Buy rating on the shares. The firm says ...

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to ...

BioNTech shares fell Monday, as the COVID-19 vaccine maker’s soft outlook offset better-than-expected quarterly results.

It comes on the heels of the FDA's top vaccine scientist Peter Marks' exit from the agency, which will be effective April 5.